TAK - Takeda gets EU approval for Fruzaqla for colorectal cancer
2024-06-21 16:33:06 ET
More on Takeda Pharmaceutical
- Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
- Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation
- Ovid stock plunges 66% on failed studies for soticlestat
- Takeda seeks licensing deal for blood cancer therapy